Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group

Blood (2023) 142 (Supplement 1): 1981.

https://doi.org/10.1182/blood-2023-181029

Published: 2023

Journal Articles

Soluble CD163; A Possible New Biomarker in Multiple Myeloma

Annita Ioanna Gkioka, Alexandros Gkiokas, Alexandros Alexandropoulos, Mavra Papadatou, Aspasia Koudouna, Bartzi Vasiliki, Thomai-Marina Tryfou, Nikolitsa Kafasi, Marie-Christine Kyrtsonis

Blood (2023) 142 (Supplement 1): 3373.

https://doi.org/10.1182/blood-2023-189519

Published: 2023

Journal Articles

The Prognostic Significance of Serum Beta-2 Microglobulin (sβ 2 m) Levels in Patients with Hodgkin Lymphoma (HL): Final Analysis on 915 Patients Treated with ABVD or Equivalent (ABVDeq) Chemotherapy or Combined Modality Therapy (CT/CMT) Focusing to the Determination of Optimal Cut-Offs

Blood (2022) 140 (Supplement 1): 12016–12017.

https://doi.org/10.1182/blood-2022-169972

Published: 2022

Journal Articles

A Study of Ribonucleotide Reductase mRNA Expression and Its Prognostic Role in Patients with Chronic Lymphocytic Leukemia

Sevastianos Chatzidavid, Christina-Nefeli Kontandreopoulou, Panagiotis T Diamantopoulos, Nefeli Giannakopoulou, Panagiota Katsiampoura, Christos Stafylidis, Georgios Dryllis, Marie-Christine Kyrtsonis, Maria Dimou, Panagiotis Panagiotidis, Nora-Athina Viniou

Blood (2021) 138 (Supplement 1): 4678.

https://doi.org/10.1182/blood-2021-150149

Published: 2021

Journal Articles

Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study

Efstathios Kastritis, Evangelos Terpos, Argiris Symeonidis, Sosana Delimpasi, Michele Cavo, Elena Zamagni, Eirini Katodritou, Elena Rivolti, Marie-Christine Kyrtsonis, Maria Roussou, Despina Fotiou, Evdoxia Hatjiharissi, Nikolaos Kanellias, Magdalini Migkou, Alexandros Leonidakis, Kyriaki Manousou, Maria Gavriatopoulou, Meletios A. Dimopoulos

Blood (2021) 138 (Supplement 1): 2729.

https://doi.org/10.1182/blood-2021-153075

Published: 2021

Journal Articles

Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study

Evangelos Terpos, Efstathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, Evangelos Eleutherakis Papaiakovou, Evgenia Verrou, Maria Gavriatopoulou, Alexandros Leonidakis, Ioannis Ntanasis-Stathopoulos, Sosana Delimpasi, Marie-Christine Kyrtsonis, Maria Papaioannou, Argiris Symeonidis, Meletios A. Dimopoulos

Blood (2021) 138 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2021-152385

Published: 2021

Journal Articles

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-138390

Published: 2020

Journal Articles

Serum Soluble Syndecan-1 (ssCD138) Can Contribute to the Discrimination of Lenalidomide Resistant Multiple Myeloma (MM) Patients

Annita Ioanna Gkioka, MD, Aspasia Koudouna, MD, Vasiliki Bartzi, MD, Maria Dimou, MD PhD, Theodoros Iliakis, MD, Aikaterini Bitsani, MD, Vasileios Pardalis, MD, Panayiotis Panayiotidis, MD, Marie-Christine Kyrtsonis, MD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142006

Published: 2020

Journal Articles

Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study

Evangelos Terpos, MDPhD, Efstathios Kastritis, MD, Evdoxia Hatjiharissi, MD, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD, Maria Papaioannou, MD, Argiris Symeonidis, MD PhD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-140261

Published: 2020

Journal Articles

Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study

Efstathios Kastritis, MD, Evangelos Terpos, MDPhD, Argiris Symeonidis, MD PhD, Sosana Delimpasi, MD, Michele Cavo, Elena Zamagni, Eirini Katodritou, MD, Elena Rivolti, MD, Marie-Christine Kyrtsonis, MD, Maria Gavriatopoulou, Maria Roussou, MD, Despina Fotiou, MD, Evdoxia Hatjiharissi, MD, Nikolaos Kanellias, MD, Magdalini Migkou, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-140322

Published: 2020

Journal Articles

Continuous Clinical Remisssion with High MRD Negativity and High PB and BM MRD Concordance during Venetoclax Monotherapy in R/R CLL Patients

Maria Dimou, MD PhD, Ioannis Anagnostopoulos, MD, Sotiria Kalyva, PhD, Vasileios Pardalis, MD, Athanasios Markopoulos, PhD, Aikaterini Bitsasni, MD, Theodoros Iliakis, MD, Marie-Christine Kyrtsonis, MD, Panayiotis Panayiotidis, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-142992

Published: 2020

Journal Articles

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, MD, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Papaioannou, Argiris Symeonidis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1837.

https://doi.org/10.1182/blood-2019-124638

Published: 2019

Journal Articles

Facilitated Subcutaneous Immunoglobulin (fSCIG) Administration in Secondary Immune Deficiency (SID) Due to Hematological Malignancies. Efficacy and Safety Real-World Data from a Single-Center in Greece

Maria Dimou, MD PhD, Vasileios Pardalis, MD PhD, Theodoros Iliakis, MD, Aikaterini Bitsani, MD, Ioannis Grafakos, MD, Sotiria Kalyva, PhD, Athanasios Markopoulos, PhD, Marie-Christine Kyrtsonis, MD PhD, Panayiotis Panayiotidis, MD

Blood (2019) 134 (Supplement_1): 3429.

https://doi.org/10.1182/blood-2019-122834

Published: 2019

Journal Articles

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Eftathios Kastritis, Evangelos Terpos, MD PhD, Argiris Symeonidis, MD PhD, Sosana Delimpasi, MD, Michele Cavo, Elena Zamagni, MD, Eirini Katodritou, MD, Barbara Gamberi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Gavriatopoulou, MD, Maria Roussou, MD, Despina Fotiou, MD, Evdoxia Hatjiharissi, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1881.

https://doi.org/10.1182/blood-2019-124630

Published: 2019

Journal Articles

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Ioannis Tsonis, MD, Nikolaos Kanellias, MD, Vasileios Lazaris, Panayiotis Panayiotidis, MD PhD, Damianos Sotiropoulos, MD, Theodoros Vassilakopoulos, MD, Zoi Arapidou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Dimitrios Boutsis, Athanasios Galanopoulos, MD PhD, Ioannis Kotsianidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Theoni Leonidopoulou, MD, Gerasimos Pangalis, MD, Maria Papaioannou, Sophia Polychronopoulou, MD PhD, Charalampos Pontikoglou, MD PhD, Elias Poulakidas, Christos Poziopoulos, MD, Panagiotis Repousis, MD, Maria Topalidou, Kalliopi Vallianatou, Elina Vervessou, MD, Nora-Athina Viniou, Maria Angelopoulou, MD, Ioannis Baltadakis, MD, Maria Dimou, MD PhD, Eleni Gavriilaki, MD, Theodoros Iliakis, MD, Argiris Symeonidis, MD PhD, Sossana Delibasi, MD, Maria Papathanassiou, Theodoros Marinakis, Panagiotis Tsirigotis, MD, Nikolaos Charchalakis, PhD, Evangelos Terpos, MD PhD, Maria Pagoni

Blood (2018) 132 (Supplement 1): 5463.

https://doi.org/10.1182/blood-2018-99-116693

Published: 2018

Journal Articles

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Blood (2018) 132 (Supplement 1): 3295.

https://doi.org/10.1182/blood-2018-99-114106

Published: 2018

Journal Articles

Uninvolved Immunoglobulin Suppression Determined By "Hevylite" ASSAY. Strongly Predicts Evolution of Smoldering Myeloma (SMM) to Symptomatic Multiple Myeloma (MM)

Paraskevi Papaioannou, MD, Annita Ioanna Gkioka, MD, Kallirroi Tsalimalma, MD, Aspasia Koudouna, MD, Anastasia Kopsaftopoulou, MD, Konstantina Chamoulkou, MD, Ioannis Grafakos, MD, Aikaterini Bitsani, MD, Theodoros Iliakis, MD, Maria Dimou, MD PhD, Nikolitsa Kafassi, MD, Petros Sfikakis, MD PhD, Panayiotis Panayiotidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD

Blood (2018) 132 (Supplement 1): 5584.

https://doi.org/10.1182/blood-2018-99-118631

Published: 2018

Journal Articles

Increased SERUM VON Willebrand Levels in Chronic Lymphocytic Leukemia (CLL) Patients Are Related to a Shorter Time to Treatment

Thommais Tryfou, MLS, Paraskevi Papaioannou, MD, Panagiotis Repousis, MD, Annita Ioanna Gkioka, MD, Sotirios Sachanas, Aikaterini Bitsani, MD, Maria Dimou, MD PhD, Dimitrios Maltezas, Aspasia Koudouna, MD, Anastasia Kopsaftopoulou, MD, Konstantina Chamoulkou, MD, Ioannis Grafakos, MD, Styliani Kokori, MD, Argyrios Tsantes, MD, Gerasimos Pangalis, MD, Panayiotis Panayiotidis, MD PhD, Marie-Christine Kyrtsonis, MD PhD

Blood (2018) 132 (Supplement 1): 5547.

https://doi.org/10.1182/blood-2018-99-119520

Published: 2018

Journal Articles

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Blood (2018) 132 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2018-99-115725

Published: 2018

Journal Articles

Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance

Blood (2018) 132 (6): 666–670.

https://doi.org/10.1182/blood-2018-02-833608

Published: 2018

NARROW

Update Analysis of Central Nervous System Multiple Myeloma Prognosis and Survival: A Real-World Multi-Institutional Study of the Greek Myeloma Study Group

Soluble CD163; A Possible New Biomarker in Multiple Myeloma

The Prognostic Significance of Serum Beta-2 Microglobulin (sβ 2 m) Levels in Patients with Hodgkin Lymphoma (HL): Final Analysis on 915 Patients Treated with ABVD or Equivalent (ABVDeq) Chemotherapy or Combined Modality Therapy (CT/CMT) Focusing to the Determination of Optimal Cut-Offs

A Study of Ribonucleotide Reductase mRNA Expression and Its Prognostic Role in Patients with Chronic Lymphocytic Leukemia

Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study

Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Serum Soluble Syndecan-1 (ssCD138) Can Contribute to the Discrimination of Lenalidomide Resistant Multiple Myeloma (MM) Patients

Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study

Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study

Continuous Clinical Remisssion with High MRD Negativity and High PB and BM MRD Concordance during Venetoclax Monotherapy in R/R CLL Patients

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Facilitated Subcutaneous Immunoglobulin (fSCIG) Administration in Secondary Immune Deficiency (SID) Due to Hematological Malignancies. Efficacy and Safety Real-World Data from a Single-Center in Greece

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Systemic Mastocytosis: Management and Outcome. Data Analysis from the Greek Registry

Real-World Data on Incidence, Clinical Characteristics and Outcome of Patients with Macrofocal Multiple Myeloma (MFMM) in the Era of Novel Therapies: A Study of the Greco-Israeli Collaborative Myeloma Working Group

Uninvolved Immunoglobulin Suppression Determined By "Hevylite" ASSAY. Strongly Predicts Evolution of Smoldering Myeloma (SMM) to Symptomatic Multiple Myeloma (MM)

Increased SERUM VON Willebrand Levels in Chronic Lymphocytic Leukemia (CLL) Patients Are Related to a Shorter Time to Treatment

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only